Clinical Trials Logo

Clinical Trial Summary

A multicenter, open-label, prospective study to evaluate the safety and efficacy of leuprorelin acetate DPS (Leuplin DPS) treatment quarterly in patients with central precocious puberty


Clinical Trial Description

Type and design of study (eg, parallel, crossover, double-blind, open, superiority, noninferiority).Blinding measures taken to minimize bias (eg, "single-blind; subjects receive blinded study medication").

A single arm, multicenter, open-label, prospective study. Requirements for run-in or washout of medication. Those who have been administered one of the following drugs within 2 weeks before they start to participate in this study

- Estrogens

- Antiestrogens

- Progesterones

- Steroids

- Oriental medicines

Description of population to be studied (eg, adults with chronic heart failure and ejection fraction below 40% or subjects with uncontrolled, long-term type 2 diabetes).

Children with central precocious puberty

- Inclusion Criteria.

1. Female children aged '≥ 4 years ~ < 9 years (8 years plus 364 days)

2. Those who fall under Tanner stage 2 at least (on condition that they started to have breast budding under the age of 8)

3. Female children who showed pubertal LH response to GnRH stimulation test (peak ≥ 7mIU/mL)

4. Those whose bone age increased by one year or more compared to their chronological age

5. Subjects and their guardians who gave written consent to participate in this study

- Exclusion Criteria.

1. Those whose bone age is 11 years and 6 months or older

2. Those secreting gonadal or adrenal cortex sex hormones in a non-LH-dependent manner

3. Those who have anaphylaxis to the IP or synthetic LHRH, or LHRH derivative

4. Those who have received GnRH analog treatment

5. Those who require treatment likely to influence the hypothalamic-pituitary-gonadal axis during the study period

6. Those receiving growth hormone

7. Those who are suspected of or diagnosed with malignant tumor

8. Patients with severe renal failure or hepatic failure, whose participation in this study is impossible in the investigator's opinion

9. Those who have been administered one of the following drugs within 2 weeks before they started to participate in this study, or who are expected to be administered during the study period

- Estrogens

- Antiestrogens

- Progesterones

- Steroids

- Oriental medicines

10. Those who have participated in another clinical study within 90 days from the date when the IP was administered

11. Those who are found to be ineligible for this study in the investigator's opinion ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03316482
Study type Interventional
Source Ajou University School of Medicine
Contact
Status Completed
Phase Phase 4
Start date June 11, 2015
Completion date December 30, 2019

See also
  Status Clinical Trial Phase
Completed NCT02920515 - Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Phase 4
Completed NCT00779103 - Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Phase 3
Not yet recruiting NCT05341128 - A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
Completed NCT04736602 - Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. Phase 3
Recruiting NCT05341115 - A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty Phase 4
Completed NCT02993926 - A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
Recruiting NCT02811471 - Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty Phase 3
Completed NCT01634321 - The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Phase 4
Recruiting NCT06129539 - A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty Phase 3
Terminated NCT02006680 - Markers of Pubertal Suppression During Therapy for Precocious Puberty
Completed NCT01278290 - Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Phase 3
Completed NCT02427958 - A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants Phase 4
Completed NCT05029622 - A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. Phase 3
Recruiting NCT06025409 - Evaluate the Efficacy and Safety of DWJ108J Phase 3
Completed NCT01467882 - Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Phase 3
Recruiting NCT00438217 - Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Phase 4